Biotricity (BTCY) Competitors $0.53 +0.05 (+10.42%) As of 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainSEC FilingsTrendsBuy This Stock BTCY vs. MLSS, DXR, GUTS, NEPH, EDAP, ICCM, WOK, ZYXI, PSTV, and TMDIFShould you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Milestone Scientific (MLSS), Daxor (DXR), Fractyl Health (GUTS), Nephros (NEPH), EDAP TMS (EDAP), IceCure Medical (ICCM), WORK Medical Technology Group (WOK), Zynex (ZYXI), Plus Therapeutics (PSTV), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry. Biotricity vs. Its Competitors Milestone Scientific Daxor Fractyl Health Nephros EDAP TMS IceCure Medical WORK Medical Technology Group Zynex Plus Therapeutics Titan Medical Milestone Scientific (NYSE:MLSS) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Does the media prefer MLSS or BTCY? In the previous week, Milestone Scientific had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for Milestone Scientific and 0 mentions for Biotricity. Milestone Scientific's average media sentiment score of 0.64 beat Biotricity's score of 0.00 indicating that Milestone Scientific is being referred to more favorably in the media. Company Overall Sentiment Milestone Scientific Positive Biotricity Neutral Do analysts rate MLSS or BTCY? Milestone Scientific presently has a consensus price target of $1.25, indicating a potential upside of 107.30%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Milestone Scientific is more favorable than Biotricity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Scientific 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Biotricity 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings & valuation, MLSS or BTCY? Milestone Scientific has higher earnings, but lower revenue than Biotricity. Milestone Scientific is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Scientific$9.08M5.22-$6.93M-$0.09-6.70Biotricity$12.06M1.09-$14.09M-$0.21-2.52 Which has more risk and volatility, MLSS or BTCY? Milestone Scientific has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Do insiders and institutionals have more ownership in MLSS or BTCY? 5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 24.8% of Milestone Scientific shares are held by company insiders. Comparatively, 10.1% of Biotricity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is MLSS or BTCY more profitable? Milestone Scientific has a net margin of -52.01% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Milestone Scientific's return on equity.Company Net Margins Return on Equity Return on Assets Milestone Scientific-52.01% -60.26% -40.23% Biotricity -80.42%N/A -188.47% SummaryMilestone Scientific beats Biotricity on 12 of the 16 factors compared between the two stocks. Get Biotricity News Delivered to You Automatically Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTCY vs. The Competition Export to ExcelMetricBiotricitySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.20M$85.42M$5.76B$9.59BDividend YieldN/AN/A4.41%4.09%P/E Ratio-0.4911.0031.1026.05Price / Sales1.09105.21470.24120.75Price / CashN/A18.4137.7358.48Price / Book-0.417.139.536.61Net Income-$14.09M-$26.48M$3.26B$265.56M7 Day Performance-15.93%-1.52%2.11%1.98%1 Month Performance3.92%-2.26%5.12%1.33%1 Year Performance10.44%57.42%31.25%21.15% Biotricity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTCYBiotricityN/A$0.53+10.4%N/A+14.8%$13.20M$12.06M-0.4940MLSSMilestone Scientific2.4207 of 5 stars$0.62+4.0%$1.25+100.3%-40.5%$48.97M$8.61M-8.9130Short Interest ↑Gap UpDXRDaxor4.2723 of 5 stars$11.38+12.8%$25.00+119.7%+28.0%$48.81MN/A0.0037Gap DownGUTSFractyl Health1.7454 of 5 stars$0.98+0.7%$11.00+1,018.0%-67.0%$47.85M$90K-0.53102NEPHNephros1.5316 of 5 stars$4.26-5.1%$5.50+29.1%+117.3%$47.60M$14.16M35.5030EDAPEDAP TMS3.0585 of 5 stars$1.36+7.9%$8.50+525.0%-67.3%$47.11M$69.18M-2.19230News CoverageUpcoming EarningsGap DownICCMIceCure Medical1.9485 of 5 stars$0.82+3.4%$2.50+204.9%+17.2%$46.55M$3.29M-2.9360WOKWORK Medical Technology GroupN/A$0.78-1.4%N/AN/A$44.72M$11.51M0.00226Positive NewsGap UpZYXIZynex2.5461 of 5 stars$1.58+11.3%$4.90+210.1%-80.2%$43.02M$192.35M-1.68770PSTVPlus Therapeutics2.8533 of 5 stars$0.73+4.4%$10.83+1,382.4%-66.9%$42.34M$5.82M-0.2520Gap DownTMDIFTitan MedicalN/A$0.37+2.3%N/A+736.0%$42.01M$17.63M-0.2950 Related Companies and Tools Related Companies Milestone Scientific Alternatives Daxor Alternatives Fractyl Health Alternatives Nephros Alternatives EDAP TMS Alternatives IceCure Medical Alternatives WORK Medical Technology Group Alternatives Zynex Alternatives Plus Therapeutics Alternatives Titan Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTCY) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotricity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access